Liver Fibrosis: Intelligent Analysis of Risk Factors
Bouharati Khaoula *
Department of Epidemiology, Faculty of Medicine, Constantine University, Algeria and Laboratory of Health and Environment, UFAS Setif1 University, Setif, Algeria.
Bouharati Imene
Faculty of Medicine, Paris Sorbonne University, France and Laboratory of Intelligent Systems, UFAS Setif1 University, Setif, Algeria.
Guenifi Wahiba
Faculty of Medicine, Setif University Hospital, UFAS Setif1 University, Setif, Algeria.
Gasmi Abdelkader
Faculty of Medicine, Setif University Hospital, UFAS Setif1 University, Setif, Algeria.
Boucenna Nassim
Faculty of Medicine, Setif University Hospital, UFAS Setif1 University, Setif, Algeria.
Laouamri Slimane
Faculty of Medicine, Setif University Hospital, UFAS Setif1 University, Setif, Algeria.
*Author to whom correspondence should be addressed.
Abstract
Background: Hepatic fibrosis is excessive scarring resulting from the buildup of connective tissue in the liver. The extracellular matrix is produced in excess and / or insufficiently degraded. Fibrosis by itself is asymptomatic but can lead to portal hypertension (fibrosis deflects intrahepatic blood flow) or cirrhosis (fibrosis destroys normal hepatic architecture and induces hepatic dysfunction). Fibrosis can sometimes develop without being linked to a known risk factor. The most common causes of liver fibrosis are hepatitis B and C and alcohol abuse.
Objectives: The objective of this study is the identification of risk factors and their effects. As the set of factors are often unknown and even those that are, their exact weights are ignored. The proposed fuzzy analysis makes it possible to deal with these inaccuracies.
Methods: As the system is very complex to analyze its factors using classical mathematical tools, this study proposes an intelligent analysis in the data processing. A fuzzy inference system is proposed. Risk factors are considered fuzzy variables and therefore uncertain. The proposed analysis system has fuzzy inputs representing risk factors, an output that expresses the degree of certainty of fibrosis affection. A database is created from the real values of cases diagnosed at the level of our hospital service. Inputs are linked to output via inference rules of the form [IF… THEN].
Conclusion: Once the system is established, this will allow variables to be introduced randomly at the inputs to automatically read the output result calculated by the aggregation of all the rules combined and therefore can predict the attack by this disease.
Keywords: Sansevieria suffruticossa, Hepatic fibrosis, aerial,, risk factors, terrestrial, intelligent modeling, dimorphic, fuzzy logic, acropetal,, exodermis, unistratose, scattered, collateral,, cencentric
How to Cite
Downloads
References
Friedman SL. Liver fibrosis -- From bench to bedside. J Hepatol. 2003;38(Suppl 1):S38-53.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51.
Mallem L1, Safir A1, Amani N1, Amar M, Belkahla MR, Hakem S1, Boumansour N2, Midoun N2. Risk factors of hepatic fibrosis at the chronic carriers of virus B followed at Oran university hospital center. Algerian Journal of Health Sciences. 2019 ;01(01) :21-26.
Llorenç Caballería, et al. High prevalence of liver fibrosis among european adults with unknown liver disease: A population-based study. Clinical Gastroenterology and Hepatology 2018;16:1138–1145.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice. Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European. Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol 2016;64:1388–1402.
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.
Satapathy SK, Sanyal AJ. epidemiology and natural history of nonalcoholic fatty liver disease.Semin Liver Dis. 2015;35:221–235.
Ginès P, Graupera I, Lammert F, et al. Screening for liver fibrosis in the general population: a call for action. Lancet Gastroenterol Hepatol. 2016;1:256–260.
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-121
[PMID: 16012941
DOI: 10.1053/ j.gastro.2005.04.014]
Sombat Treeprasertsuk, Einar Björnsson, Felicity Enders, Sompongse Suwanwalaikorn, Keith D Lindor. NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219-1229
World health organization. Global hepatitis report, 2017. Geneva : WHO; 2017.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer. 2015;136:E359-86.
Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383,98.
DOI:https://doi.org/10.1016/j.cld.2005.05.003
Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44:S19–S24
DOI:https://doi.org/10.1016/j.jhep.2005.11.009
Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 1997;26:122S–127S.
DOI: https://doi.org/10.1002/hep.510260721.
Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001;34:730–739.
Sulkowski MS, Thomas DL. Hepatitis C in the HIV-Infected Person. Ann Intern Med. 2003;138:197–207.
Bouharati Khaoula, Bouharati Imene, Laouamri Slimane. Air Pollution and Health Risk: Intelligent Mapping. Journal of Oral Surgery Oral Pathology and Oral Medicine. An Official Publication of Bureau for Health & Education Status Upliftment. (Constitutionally Entitled As Health-Education, Bureau). 2022;17(1):1-9.
Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol. Int. 2009; 3:425–433.
Sadhna Dhingra, Stephen C Ward, and Swan N Thung. Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol. 2016; 22(4):1357–1366.
DOI: 10.3748/wjg.v22.i4.1357
Becker U, Deis A, Sørensen T, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996; 23:1025-9.
Abdulmudallib I, Alao BO, Thankgod J. Assessment of knowledge and acceptance of hepatitis (B and C) virus vaccine among pregnant women attending antenatal care at Specialist Hospital Taraba State- Nigeira. Asian Journal of Research in Medicine and Medical Science. 2022; 4(1):32-39.
Available: https://globalpresshub.com/index.php/AJRMMS/article/view/1473